iX Biopharma Ltd.
iX Biopharma Ltd. (SES: 42C) is trading at S$0.56, about ₹42 at today's SGD/INR rate, as of 25 Sep 2026, 5:04 AM ET, down 5.88% today. Indian residents can buy iX Biopharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
S$0.56
Today's high
S$0.61
52 week low
S$0.04
52 week high
S$0.63
42C opened at S$0.59, closed previously at S$0.60, and has traded between S$0.04 and S$0.63 over the past 52 weeks.
About
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise headquartered in Singapore since its inception in 2004, focuses on the research, development, manufacturing, and commercialization of therapeutic solutions. The company targets acute and breakthrough pain, alongside various other health conditions, serving markets in Singapore, the United States, China, and Australia through its Specialty Pharmaceutical and Nutraceutical divisions. Its commercial offerings include Wafesil and Silcap, both indicated for male erectile dysfunction. Additionally, the company markets Xativa, a sublingual cannabidiol wafer, and Hypera, a sublingual tetrahydrocannabinol wafer, which address chronic pain, anxiety, and insomnia. iX Biopharma boasts an extensive product pipeline. Wafermine, a racemic ketamine sublingual wafer designed for complex regional pain syndrome and psychiatric conditions like depression, has successfully advanced through Phase 2 clinical trials. Other investigational candidates that have completed Phase 1 trials include iXB 120 for acute agitation, IXB-214 for complex regional pain syndrome, and IXB-314 for treatment-resistant depression. Furthermore, BnoX is currently undergoing Phase 1 evaluation for moderate to severe pain. In earlier development stages, iXB 401, a sublingual semaglutide wafer, is in pre-clinical development for Type 2 Diabetes and obesity. The pipeline also encompasses SL-NAD+, a sublingual NAD+ wafer engineered to boost the body's NAD+ levels, energy, and alertness; a distinct NAD+ product targeting sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafer for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer offering benefits for skin brightening and immunity.
Key statistics
Avg. volume
14.97M
Market cap
S$612.26M
P/E Ratio
-67.47
Price-to-sales ratio
89.34
Enterprise value
S$603.32M
Free cash flow yield
-0.93%
Debt-to-equity ratio
0.38
Return on equity
-81.85%
ROIC
-44.68%
Beta
1.08
Dividend yield
0.00%
Last dividend
S$0.00
Financial overview
Revenue
S$6.85M
Earnings per share
-S$0.01
Free cash flow
-S$8.07M
Net profit margin
-116.64%
Gross margin
35.52%
EBITDA
-S$8.83M
Revenue growth
-11.77%
Similar securities
This is not an investment recommendation
How to buy iX Biopharma from India
Indian residents can buy iX Biopharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to SGD.
Search for iX Biopharma and place an order
Find iX Biopharma by name or by its ticker, 42C, and choose an order type. iX Biopharma trades 6:30 am – 2:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your iX Biopharma position in SGD and INR. iX Biopharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in iX Biopharma from India
Trading and taxes when buying iX Biopharma from India
Trading and limits
- Trading hours
- 9:00 am – 5:00 pm SGT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneiX Biopharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- Transaction tax
- Singapore levies no stamp duty or transaction tax on listed equities.
- Estate or inheritance tax
- May applySingapore imposes no estate or inheritance tax on listed securities.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy iX Biopharma stock?
Yes. iX Biopharma (42C) has been listed on the Singapore Exchange since 2015, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to SGD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one iX Biopharma share cost in rupees?
One iX Biopharma share is S$0.56 — about ₹42 at an SGD/INR rate of 75.02 on 24 Sep 2026. Both the iX Biopharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying iX Biopharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on iX Biopharma shares taxed in India?
Singapore does not levy capital gains tax on the sale of shares, ETFs or REITs, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the SGD/INR rate on the purchase and the sale date, so the rupee move counts alongside the iX Biopharma price. Paasa issues a capital-gains statement for your return.
Does iX Biopharma pay a dividend?
No. iX Biopharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade iX Biopharma from India?
The Singapore Exchange trades 6:30 am – 2:30 pm IST in Indian time. Orders can only execute during that window.
Is there estate or inheritance tax on iX Biopharma shares held from India?
Singapore imposes no estate or inheritance tax on listed securities.
Are there transaction taxes when buying iX Biopharma?
Singapore levies no stamp duty or transaction tax on listed equities.
Do I have to declare iX Biopharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your iX Biopharma holding, its cost and its closing value.
How do I sell iX Biopharma and bring the money back to India?
You sell during market hours (6:30 am – 2:30 pm IST) and the proceeds settle in SGD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.